Amneal Targets Migraine With 505(b)(2) Filing

Pursues Headache Market In US With Dihydroergotamine Autoinjector

 
• By Dave Wallace

Amneal is setting its sights on the migraine and cluster headache market in the US with a new hybrid 505(b)(2) filing for a dihydroergotamine autoinjector.

Headache Migraine Pain
Amneal is targeting migraine and cluster headache • Source: Alamy

More from Value Added Medicines

More from Products